#1

Mice treated in middle age were much stronger etc in old age. There’s a US company working with us. Problem, as always, they have to go through the overly-long FDA process, and they can only do trials for a specific disease rather than for aging.

4 Likes
#2

Seems they changed their name to Klotho Neurosciences https://ir.klothoneuro.com/

2 Likes
#3

Here’s the Cell research article https://www.cell.com/molecular-therapy-family/molecular-therapy/fulltext/S1525-0016(25)00120-0

2 Likes
#4

Klotho Neurosciences (KLTO) witnessed an astonishing 800% increase in stock value on June 9, 2025, after revealing positive results from pre-clinical studies. The company’s investigations indicated that enhancing Klotho gene expression may significantly lessen age-related deterioration across various organs while prolonging both lifespan and healthspan.

The focus of Klotho’s research is on the secreted protein s-KL, which has been identified as a potential anti-aging treatment owing to its wide-ranging biological impacts across various pathways linked to cellular damage, stress, and inflammation. In pre-clinical trials, the company employed an adeno-associated virus serotype 9 (AAV9) delivery vector to express the secreted KL protein isoform, successfully boosting serum s-KL levels and achieving a remarkable 20% increase in lifespan. [1]

This method tackles aging as a key risk factor that contributes to numerous health issues, such as cognitive decline, neuroinflammation, sarcopenia, and osteoporosis.

Read the full story:

2 Likes
#5

The company currently does not generate any revenue and has reported a negative net income of around $8 million over the past twelve months.

They have 3 employees. The stock is currently worth 65 million. Interesting. Is this a buy @DeStrider ?

1 Like
#6

Look up Liz Parrish, the most genetically modified person, we know of.

In 2015 she did Klotho gene therapy as well as Telomere gene therapy and has not looked back in her quest for meaningful extension of life span. I can agree that health span is probably increased but not extending “life span” past the hard stop at 120.

#7

Follistatin and telomere. You can get better muscles and Klotho with exercise, and throw in about a dozen other things it does. And extending telomeres can cause cancer? More power to her and I hope it works, but I’m not nearly there yet with the gene therapy.

She could do it in this country as far as I’m concerned. I don’t know what the fuss is about.

#8

I agree on doing it in this country. If we’re a free nation, then people should be able to make their own decisions about these things.

#9

It’s a penny stock currently trading at $1.57 so that kind of move in a penny stock with good news is not unusual. Of course, it’s a huge risk, & sometimes there’s manipulation in these thinly trading pennies.

3 Likes
#10

Klotho Neurosciences Moves Forward with Manufacturing Gene Therapy for the Treatment of ALS

Klotho Neurosciences, Inc. (NASDAQ: KLTO ) today announced that it is moving forward with manufacturing and process development work in preparation for clinical trials of KLTO-202, its investigational gene therapy for amyotrophic lateral sclerosis (ALS).

A unique RNA splice variant of the human gene called alpha-Klotho has been licensed by the Company from the Autonomous University of Barcelona (“UAB”) including patents, patent applications, research, knowhow and other intellectual properties for use in the development of advanced gene and gene-engineered cell therapies. The human alpha-Klotho gene is located in cells found throughout the human body. It is a five exon gene that produces two protein isoforms: a full-length protein found mainly in cells of the kidney called membrane-bound Klotho (or m-KL), which controls phosphate homeostasis, and a much smaller protein isoform called secreted alpha-Klotho (or s-KL). The s-KL RNA splice variant is found mainly in the brain and spinal cord neurons; the variant protein is neuroprotective by minimizing both oxidative stress and neuroinflammation.

The Company expects that it will take approximately eight months to complete process development and manufacturing of KLTO-202, and about four to six months to conduct meetings with FDA, complete all FDA-mandated animal safety studies, file an investigational new drug application (IND), train and prepare clinical sites where the Phase I/II studies can be conducted, and then begin the single-dose gene therapy studies in ALS patients by the third quarter of next year.

4 Likes
#11

I hope they have success. ALS is such a horrible disease.

#12

Exciting and will be fun to watch this one. It occurs to me though that if this is so great our bodies should have figured it out long ago and just make ourselves a little more. There is probably a down side.